NASDAQ:PPBT
Purple Biotech Ltd. Stock News
$0.510
-0.0154 (-2.93%)
At Close: May 07, 2024
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher
10:56am, Wednesday, 13'th Mar 2024
Purple Biotech Ltd. Sponsored ADR (PPBT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.
PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023
11:52pm, Tuesday, 05'th Mar 2024
Purple Biotech (NASDAQ: PPBT ) just reported results for the fourth quarter of 2023. Purple Biotech reported earnings per share of -19 cents.
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
07:00am, Tuesday, 18'th Apr 2023
REHOVOT, Israel, April 18, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, e
Purple Biotech to Present at the Jefferies London Healthcare Conference
07:30am, Wednesday, 03'rd Nov 2021
REHOVOT, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and dur
Purple Biotech to Present at the Jefferies Virtual Healthcare Conference
07:38am, Wednesday, 26'th May 2021
REHOVOT, Israel, May 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durabl
Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
07:00am, Thursday, 20'th May 2021
Initial Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Solid Tumors and Head and Neck Cancer to be Highlighted
Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors
07:00am, Wednesday, 19'th May 2021
REHOVOT, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and dura
Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients
08:00am, Friday, 23'rd Apr 2021
Preliminary Data from First Part of Study Anticipated in Second Half of 2021
Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
08:17am, Tuesday, 13'th Apr 2021
TEL AVIV, Israel, April 13, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and d
Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers
08:00am, Friday, 19'th Mar 2021
Study Being Conducted in Clinical Collaboration with Bristol Myers Squibb
Purple Biotech to Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
08:02am, Thursday, 11'th Mar 2021
TEL AVIV, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” ”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effec
Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors
07:00am, Wednesday, 03'rd Mar 2021
Rehovot, Israel, March 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and durable therapies
PPBT Stock: 9 Things for Investors to Know About Purple Biotech as Shares Surge
12:07pm, Wednesday, 10'th Feb 2021
Purple Biotech (PPBT) stock is heading higher on Wednesday with heavy trading of the shares despite a lack of news about the company. The post PPBT Stock: 9 Things for Investors to Know About Purple B
Purple Biotech to Present at the B. Riley Oncology Investor Conference
07:41am, Monday, 18'th Jan 2021
REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune